Construction of drug network based on side effects and its application for drug repositioning

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ye, Hao ^a   Liu, Qi ^b   Wei, Jia ^a  

^a ASTRAZENECA   (United Kingdom)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIMYCOBACTERIAL AGENT; ANTIOBESITY AGENT; LAXATIVE;

ADVERSE DRUG REACTION; ARTICLE; CLINICAL PROTOCOL; COMPUTER NETWORK; DIABETES MELLITUS; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG INDICATION; DRUG INFORMATION; DRUG REPOSITIONING; DRUG SCREENING; EXPRESSION ANALYSIS SYSTEMATIC EXPLORER SCORE; FISHER EXACT TEST; FOOD AND DRUG ADMINISTRATION; MATHEMATICAL COMPUTING; MEDICAL INFORMATION SYSTEM; OBESITY; PREDICTION; SCORING SYSTEM; ALGORITHM; DRUG DATABASE; HUMAN; REPRODUCIBILITY; THEORETICAL MODEL;

ALGORITHMS; DATABASES, PHARMACEUTICAL; DRUG REPOSITIONING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS;

EID: 84895194983     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087864     Document Type: Article

References (51)

1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, et al. (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9: 203-214.
2. David E, Tramontin T, Zemmel R (2009) Pharmaceutical R&D: the road to positive returns. Nat Rev Drug Discov 8: 609-610.
3. Berggren R, Moller M, Moss R, Poda P, Smietana K (2012) Outlook for the next 5 years in drug innovation. Nat Rev Drug Discov 11: 435-436.
4. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715. (Pubitemid 39173511)
5. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683. (Pubitemid 39173508)
6. Wu Z, Wang Y, Chen L (2013) Network-based drug repositioning. Mol Biosyst 9: 1268-1281.
7. Oprea TI, Mestres J (2012) Drug repurposing: far beyond new targets for old drugs. AAPS J 14: 759-763.
8. Liu X, Zhu F, Ma XH, Shi Z, Yang SY, et al. (2013) Predicting targeted polypharmacology for drug repositioning and multi- target drug discovery. Curr Med Chem 20: 1646-1661.
9. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935. (Pubitemid 44497995)
10. Luo H, Chen J, Shi L, Mikailov M, Zhu H, et al. (2011) DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res 39: W492-498.
11. Dakshanamurthy S, Issa NT, Assefnia S, Seshasayee A, Peters OJ, et al. (2012) Predicting new indications for approved drugs using a proteochemometric method. J Med Chem 55: 6832-6848.
12. Cheng F, Zhou Y, Li J, Li W, Liu G, et al. (2012) Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. Mol Biosyst 8: 2373-2384.
13. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, et al. (2012) Use of genome-wide association studies for drug repositioning. Nat Biotechnol 30: 317-320.
14. Ye H, Tang K, Yang L, Cao Z, Li Y (2012) Study of drug function based on similarity of pathway fingerprint. Protein Cell 3: 132-139.
15. Ye H, Yang L, Yang L, Cao Z, Tang K, Li Y (2012) A pathway profile-based method for drug repositioning. Chin Sci Bull 57: 2106-2112.
16. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, et al. (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107: 14621-14626.
17. Gottlieb A, Stein GY, Ruppin E, Sharan R (2011) PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 7: 496.
18. Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10: 428-438.
19. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815. (Pubitemid 44086621)
20. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P (2010) A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 6: 343.
21. Yang L, Agarwal P (2011) Systematic drug repositioning based on clinical sideeffects. PLoS One 6: e28025.
22. Duran-Frigola M, Aloy P (2012) Recycling side-effects into clinical markers for drug repositioning. Genome Med 4: 3.
23. Ye H, Tang K, Li Y (2012) Drug-Drug Network Based on Similarity of Molecular Fingerprint. Journal of East China University of Science and Technology 3: 301-306.
24. Aronson JK (2006) Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (Fifteenth Edition).
25. Aronson JK (2007-2012) Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions and interactions. Volume 29-34.
26. Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4: R70.
27. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
28. Jarvelin K, Kekalainen J (2002) Cumulated gain-based evaluation of IR techniques. ACM Transactions on Information Systems 20: 422-446. (Pubitemid 44642296)
29. Sundy JS (2001) COX-2 inhibitors in rheumatoid arthritis. Curr Rheumatol Rep 3: 86-91.
30. Robinson DR, Tashjian AH, Levine L (1975) Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest 56: 1181-1188.
31. Bingham CO (2002) Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve Clin J Med 69: SI5-12.
32. Truong DD (2009) Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging 4: 109-113.
33. Borges N (2005) Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf 4: 69-73.
34. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, et al. (2005) The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 5: 49-53. (Pubitemid 40220617)
35. Arias B, Serretti A, Lorenzi C, Gasto C, Catalan R, et al. (2006) Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 90: 251-256. (Pubitemid 43185979)
36. Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E (2009) The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 203: 155-160.
37. Yoshida K, Higuchi H, Takahashi H, Kamata M, Sato K, et al. (2008) Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol 23: 121-128. (Pubitemid 351359584)
38. Benedetti F, Dallaspezia S, Colombo C, Lorenzi C, Pirovano A, et al. (2010) Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur Psychiatry 25: 476-478.
39. Spronk D, Arns M, Barnett KJ, Cooper NJ, Gordon E (2011) An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. J Affect Disord 128: 41-48.
40. Aberg E, Fandino-Losada A, Sjoholm LK, Forsell Y, Lavebratt C (2011) The functional Val158Met polymorphism in catechol-O-methyltransferase (COMT) is associated with depression and motivation in men from a Swedish population-based study. J Affect Disord 129: 158-166.
41. Prada DM, Borgulya J, Napolitano A, Zurcher G (1994) Improved therapy of Parkinson's disease by tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine sparing effect. Clin Neuropharmacol 17: S26-S37.
42. Bressa GM (1994) S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 154: 7-14.
43. Moreau JL, Borgulya J, Jenck F, Martin JR (1994) Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol 5: 344-350. (Pubitemid 24217297)
44. Fava M, Rosenbaum JF, Kolsky AR, Alpert JE, Nierenberg AA, et al. (1999) Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol 19: 329-335. (Pubitemid 29344846)
45. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, et al. (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 260: 275-285.
46. Driessen B, Reimann W (1992) Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol 105: 147-151.
47. Desmeules JA, Piguet V, Collart L, Dayer P (1996) Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 41: 7-12. (Pubitemid 26009905)
48. Tayal V, Kalra BS, Chawla S (2008) Evaluation of antidepressant activity of tramadol in mice. Indian J Pharmacol 40: 129-130.
49. Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA (2009) Opiates as antidepressants. Curr Pharm Des 15: 1612-1622.
50. Chowta MN, Manjunath M, Gopalakrishna HN, Gokul P (2011) Evaluation of role of noradrenergic system in the antidepressant activity of tramadol using tail suspension test in Albino mice. J Pharmacol Pharmacother 2: 281-282.
51. Rojas-Corrales MO, Gibert-Rahola J, Mico JA (1998) Tramadol induces antidepressant-type effects in mice. Life Sci 63: PL175-180. (Pubitemid 29369111)